The formulation change for the Lipitor molecule is interesting in that it very well might be classified as a NCE. It's an active metabolite, another FDA debate:) COOL STUFF!
the figures at the end of the patent application you posted show lipid peroxide lowering effect of various statins with EPA.
However, combo data to be published in this quarter are regarding PharmacoKinetic studies, Fixed Dose Combination (FDC) of Vascepa+Statin combo pill vs. Vascepa and statin (two pills taken together), so we can't really figure out which is THE ONE
News 
Market Data 
Discover 
